Drew Deniger

2022

In 2022, Drew Deniger earned a total compensation of $949.1K as VP, Research and Development at ZIOPHARM Oncology.

Compensation breakdown

Bonus$103,672
Option Awards$481,229
Salary$345,572
Other$18,640
Total$949,113

Deniger received $481.2K in option awards, accounting for 51% of the total pay in 2022.

Deniger also received $103.7K in bonus, $345.6K in salary and $18.6K in other compensation.

Rankings

In 2022, Drew Deniger's compensation ranked 3,135th out of 5,736 executives tracked by ExecPay. In other words, Deniger earned more than 45.3% of executives.

ClassificationRankingPercentile
All
3,135
out of 5,736
45th
Division
Manufacturing
1,763
out of 3,125
44th
Major group
Chemicals And Allied Products
831
out of 1,416
41st
Industry group
Drugs
775
out of 1,317
41st
Industry
Pharmaceutical Preparations
565
out of 963
41st
Source: SEC filing on April 25, 2023.

Deniger's colleagues

We found two more compensation records of executives who worked with Drew Deniger at ZIOPHARM Oncology in 2022.

2022

Kevin Boyle

ZIOPHARM Oncology

Chief Executive Officer

2022

Melinda Lackey

ZIOPHARM Oncology

SVP, Legal & Administration

News

In-depth

You may also like